Treatment
Dapagliflozin clinical trials
We’re tracking 85 recruiting studies that include Dapagliflozin, each written for real people, not researchers, below.
Recruiting studies
- NCT06711185RecruitingPhase 3
Can dapagliflozin protect breast cancer patients' hearts during chemo?
This trial tests if a diabetes medicine called dapagliflozin (also known as Farxiga) can protect the hearts of women with breast cancer while they receive anthracycline chemotherapy. You would take the medicine and have heart MRI scans to see if it helps prevent heart damage.
Campinas, São PauloAges 18 years+ - NCT07601867Recruiting
Dapagliflozin to improve heart function after bypass surgery
This trial tests whether a diabetes medication called dapagliflozin can help improve how well the right side of your heart works after off-pump coronary artery bypass grafting surgery (a way to reroute blood around blocked heart arteries). The goal is to see if this drug reduces strain on your heart during recovery.
Pyatigorsk, Stavropol KrayAges 18 years+ - NCT06155604RecruitingPhase 2
SGLT2 inhibitor for lupus nephritis with kidney disease
This study tests if an SGLT2 inhibitor can help protect kidney function in people who have lupus nephritis (kidney inflammation caused by lupus) and chronic kidney disease (CKD). The goal is to see if this medicine can slow down further kidney damage.
Hong KongAges 18 years+ - NCT05345327RecruitingPhase 3
First diabetes pill to protect kidneys
This Phase 3 trial tests whether starting a diabetes medicine called dapagliflozin can better slow kidney damage than starting metformin in adults with type 2 diabetes. It may help preserve kidney function over time and reduce future kidney decline.
Sydney, New South WalesAges 18 years+ - NCT07491042Recruiting
A study of SGLT2 inhibitors for people on peritoneal dialysis
This study tests whether a type of diabetes medicine called SGLT2 inhibitors (which help lower blood sugar and protect the kidneys) can benefit people who are on chronic peritoneal dialysis. You may be able to join if you are 13 or older, have some urine output, and do not have certain other health issues.
NizwaAges 13 years+ - NCT07491718Recruiting
MRI with manganese for takotsubo cardiomyopathy
This study uses a special MRI with a contrast agent called manganese to look at how the heart works in people with takotsubo cardiomyopathy (broken heart syndrome). It may help doctors understand why this condition happens and how to treat it better.
EdinburghAges 18 years+ - NCT07405216RecruitingPhase 4
SGLT2 inhibitors for teens with early kidney disease
This trial tests whether a type of medicine called SGLT2 inhibitors can help teenagers with early-stage chronic kidney disease. It looks at how safe and effective these drugs are for slowing down kidney damage.
Aguascalientes, AguascalientesAges 14–18 - NCT07379333RecruitingPhase 3
Testing a new drug for type 2 diabetes when metformin and dapagliflozin aren't enough
This study tests a new medicine (HM11260C) to see if it helps people with type 2 diabetes who are already taking metformin and dapagliflozin but still have high blood sugar. If you qualify, it could give you a new option to better control your diabetes.
Gyeonggi-doAges 19 years+ - NCT07297589RecruitingPhase 3
CT scan of heart fat after heart attack
This study uses a CT scan to look at the layer of fat around the heart in people who recently had a heart attack and have type 2 diabetes and obesity. It aims to understand how this fat relates to inflammation and heart health.
León, GuanajuatoAges 18 years+ - NCT06875193RecruitingPhase 4
Comparing dapagliflozin vs pioglitazone for type 2 diabetes
This study is testing two different diabetes pills—dapagliflozin or pioglitazone—in people with type 2 diabetes. The goal is to see which one works better when added to your current metformin and DPP-4 inhibitor. You may qualify if your blood sugar is not well controlled with your current medications.
SeoulAges 19 years+ - NCT07295223RecruitingPhase 3
GLP-1 and SGLT2 drugs for heart attack recovery
This trial tests if combining GLP-1 and SGLT2 medications can reduce inflammation and improve heart function after a heart attack in people with type 2 diabetes and obesity. It looks for patients with a specific type of heart attack, elevated CRP levels, and preserved heart pumping ability.
León, GuanajuatoAges 18 years+ - NCT07280585RecruitingPhase 3
Testing a diabetes drug to slow kidney disease progression
This study tests whether a common diabetes medication (SGLT2 inhibitor) can help people with autosomal dominant polycystic kidney disease (ADPKD) maintain kidney function longer. If you have fast-growing kidney cysts and are between 18 and 60 years old, this trial may be an option.
FeldkirchAges 18–60 - NCT07273838RecruitingPhase 2
SGLT2 inhibitor for acute heart and kidney failure
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
New Haven, ConnecticutAges 18–85 - NCT07254572RecruitingPhase 4
Comparing diabetes drugs for heart health in prediabetes
This trial tests whether certain diabetes medications can help prevent worsening of heart disease in people who have prediabetes (higher than normal blood sugar, but not yet diabetes). It may be a good fit if you have known coronary artery disease and prediabetes.
WarsawAges 18–80 - NCT07239570RecruitingPhase 4
Using biomarkers to personalize kidney disease treatment
This study tests if matching treatments to your specific kidney disease markers can better protect your kidneys. It looks at how well Finerenone, Dapagliflozin, and Semaglutide work alone or in a sequence.
HerlevAges 18–75 - NCT05852704RecruitingPhase 3
Dapagliflozin to prevent irregular heart rhythm after bypass surgery
This trial looks at whether dapagliflozin (a diabetes medicine that helps the kidneys and heart) can lower the chance of atrial fibrillation, an irregular heart rhythm, after coronary artery bypass (CABG) surgery. If you’re scheduled for planned bypass surgery, this study may help reduce post-operative rhythm problems.
BrnoAges 18 years+ - NCT07214818RecruitingPhase 2/Phase 3
SGLT2 Inhibitors for Adult Primary Nephrotic Syndrome
This trial tests whether SGLT2 inhibitors (a type of diabetes medicine) can help adults with primary nephrotic syndrome, a kidney disease that causes protein leakage and swelling. It aims to see if the drug can protect kidney function and reduce protein loss.
Al Mansurah, Dakahlia GovernorateAges 18 years+ - NCT07174687RecruitingPhase 2
SGLT2 inhibitor for geographic atrophy
This study tests an SGLT2 inhibitor (dapagliflozin) as a possible treatment for geographic atrophy, a progressive form of dry age-related macular degeneration that causes vision loss. It is for people who meet specific eye and health criteria.
St Louis, MissouriAges 50 years+ - NCT07147114RecruitingPhase 4
Combined macitentan and dapagliflozin for heart failure with lung high blood pressure
This trial tests whether adding two medications—macitentan and dapagliflozin—together is safe and effective for people with heart failure and a certain type of high blood pressure in the lungs. It might help improve your symptoms and daily function.
BusanAges 19 years+ - NCT07082114RecruitingPhase 3
Testing a new tablet for type 2 diabetes
This study tests a new pill called HDM1002 for adults with type 2 diabetes. It aims to see if it helps control blood sugar when added to your current metformin treatment.
Yueyang, HunanAges 18–75 - NCT06982079RecruitingPhase 3
SGLT2 inhibitors for advanced kidney disease
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
CairoAges 18 years+ - NCT07056699RecruitingPhase 3
Study on diabetes drugs and ketone production in type 1 diabetes
This trial tests how two diabetes medications, SGLT2i and pioglitazone, affect ketone production in people with type 1 diabetes. It aims to find new ways to improve blood sugar control.
San Antonio, TexasAges 18 years+ - NCT07018622RecruitingPhase 2
Protecting kidneys from platinum chemotherapy damage
This trial tests a way to protect your kidneys while you receive platinum-based chemotherapy (cisplatin or carboplatin) for a solid tumor. It may help reduce the risk of kidney damage so you can complete your treatment more safely.
México, TlalpanAges 18 years+ - NCT07019012RecruitingPhase 4
Testing a new every-2-week pill for type 2 diabetes
This study tests a new once-every-2-weeks pill (cofrogliptin) added to your current diabetes medications (metformin and dapagliflozin) compared to a daily pill (linagliptin). It may help improve blood sugar control with fewer daily pills.
Wuhan, HubeiAges 18 years+
Common questions
- Are there clinical trials studying Dapagliflozin?
- Yes. Clin2 currently lists 85 recruiting studies that include Dapagliflozin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Dapagliflozin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Dapagliflozin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Dapagliflozin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.